FILING ANALYSIS · TUESDAY, NOVEMBER 10
Scholar Rock Holding Corp SRRK — 8-K: Entry into a Material Definitive Agreement
positive
Scholar Rock agreed to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech for $205 million, a significant cash infusion, and reported early demand for its newly launched therapy ISEMBYLD, with Q3 revenue of $0.6 million
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →